Alnylam Pharmaceuticals, Inc. and Glaxosmithkline Plc.– Major Players in RNAi Therapeutics Market

 

RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development.

Market leaders operating in the market have undertaken various organic growth strategies in the RNAi therapeutics market. The RNAi therapeutics market majorly consists of the players such Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Glaxosmithkline Plc., Benitec Biopharma, Arbutus Biopharma Corporation, Silence Therapeutics, Rexahn Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc, and Quark amongst others. Several organic approaches, such as product launches, and expansion/relocation in the RNAi therapeutics market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.

Below is the list of the growth strategies done by the players operating in the RNAi therapeutics market:

Year

News

Nov-2019

Alnylam Pharmaceuticals, Inc got FDA approval for its Givlaari, a very first subcutaneously administered RNAi therapy for the treatment of acute hepatic porphyria (AHP).

Dec-2018

Benitec Biopharma completed phase 2 clinical trial of its RNAi therapy candidate BB-401 for the treatment of head and neck squamous cell carcinoma (HNSCC). The study was conducted in Russia and Australia.

Mar-2018

OliX Pharmaceuticals, Inc. got clinical trial approval from Medicines and Healthcare products Regulatory Agency (MHRA), UK to conduct phase 1 trial for the drug candidate OLX10010. Olix Pharma is developing this drug for the treatment of hypertrophic scar.

Aug-2017

Rexahn Pharmaceuticals, Inc. received New U.S. Patent for Supinoxin which is a small molecule modulator of the β-catenin pathway- a key biological pathway that is activated in tumor cells.

 

Comments

Post a Comment

Popular posts from this blog

Education and Learning Analytics Market Covid-19 Impact | Analysis by Current Industry Status & Growth Opportunities and Top Key Players 2027

  The global education and learning analytics market was valued at US$ 3890.3 million in 2020 and is expected to reach US$  16,835.9 millionby 2027; it is expected to grow at a CAGR of 23.3% from 2020 to 2027. Learning analytics has emerged from varied branches of science, including psychology, statistics, sociology, data mining, information science, and machine learning, to understand data collected during teaching, learning, and education administration, among other services. Thus, learning analytics signify analysis of a huge volume of data originated and gathered from several sources by students and researchers for evaluating the performance assessment of students. Usually, learning analytics is restricted to evaluate student performance; however, with growing progress in the market, it has extended to business enterprises as workforce management. The workforce management is performed through gathering and analysing the data, anticipating the workload, assessing the ...
Read more

Pancreatic Cancer Therapy Market Size, Growth, Analysis by Recent Trends, Development and Forecast To 2025

  Rise in number of patients suffering with pancreatic cancer is driving the market for pancreatic cancer therapy over the forecast period According to The Insight Partners market research study titled ‘Pancreatic Cancer Therapy Market - Global Analysis and Forecasts By Type, Therapy, the global pancreatic cancer therapy market is expected to reach US$ 4,056.4 Mn in 2025 from US$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8.1% from 2018-2025. The report highlights the trends prevalent in the global pancreatic cancer therapy market and the factors driving the market along with those that act as deterrents to its growth. Global pancreatic cancer therapy market, based on the type was segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as t...
Read more

Automatic Checkweigher Market is estimated to accumulate US$ 342.4 Mn by 2027, says The Insight Partners

  Automatic Checkweigher Market  to 2027 - Global Analysis and Forecasts By Type (Standalone Systems, Combination Systems); Technology (Strain Gauge, Electro Magnetic Force Restoration (EMFR)); End-user Industry (Food and Beverages, Pharmaceuticals, Consumer Products, Cosmetics and Personal Care, Others) The global automatic checkweigher market accounted for US$ 235.2 Mn in 2018 and is expected to grow at a CAGR of 4.6% over the forecast period 2019–2027, to account for US$ 342.4 Mn by 2027.   The checkweighers made up of stainless steel components can withstand harsh conditions and repeated contact with water.  Other materials can be painted with the materials that can impart resistance to damages, but these will not hold up to unrelenting or washdown environments. Most of the load cells are made of aluminum.  These operate well and cost less than stainless steel load cells, but they are not designed to handle contact with water or other corrosives. They ...
Read more